AVT32-DRL_PB
Phase 1Biologic
AVT32-DRL_PB is one of 36 biologic programs targeting Melanoma. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
947 competitors in Melanoma
#DrugCompanyPhaseTrials
1Tecentriq
RochePhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
CC 5013
Bristol-Myers SquibbPhase 3
Methylphenidate Hydrochloride
TakedaPhase 3
Adjuvant Therapy
FFudan University
Phase 3
Bempegaldesleukin
NNektar Therapeutics
Phase 3
Interferon-Alpha-2a
RochePhase 3
Anti-PD1
PfizerPhase 3
Zelboraf
CConrado Roberto Hoffmann Filho
Preclinical
Intron a
Merck & Co.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AVT32-DRL_PB. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- AAlvotech Swiss AG